Michael Wessolly
Overview
Explore the profile of Michael Wessolly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Stephan-Falkenau S, Streubel A, Mairinger T, Kollmeier J, Misch D, Thiel S, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293366
Precision oncology and immunotherapy have revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). Emerging studies show that targeted therapies are also beneficial for patients with driver alterations such as...
12.
Mathilakathu A, Wessolly M, Mairinger E, Uebner H, Kreidt D, Brcic L, et al.
Int J Mol Sci
. 2022 Mar;
23(6).
PMID: 35328699
Background: Malignant pleural mesothelioma (MPM) has an infaust prognosis due to resistance to systemic treatment with platin-analoga. MPM cells modulate the immune response to their benefit. They release proinflammatory cytokines,...
13.
Wessolly M, Mairinger F, Herold T, Hadaschik B, Szarvas T, Reis H
Genes (Basel)
. 2022 Mar;
13(3).
PMID: 35327977
In recent years, the number and type of treatment options in advanced bladder cancer (BC) have been rapidly evolving. To select an effective therapy and spare unnecessary side effects, predictive...
14.
Wessolly M, Mairinger E, Borchert S, Bankfalvi A, Mach P, Schmid K, et al.
Front Oncol
. 2022 Mar;
12:798680.
PMID: 35311102
Background: High-grade serous ovarian cancer (HGSOC) is the predominant and deadliest form of ovarian cancer. Some of its histological subtypes can be distinguished by frequent occurrence of cancer-associated myofibroblasts (CAFs)...
15.
Wessolly M, Stephan-Falkenau S, Streubel A, Wiesweg M, Borchert S, Mairinger E, et al.
BMC Cancer
. 2022 Jan;
22(1):46.
PMID: 34996407
Background: Immune checkpoint inhibitors (ICIs) are currently one of the most promising therapy options in the field of oncology. Although the first pivotal ICI trial results were published in 2011,...
16.
Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, et al.
Transl Lung Cancer Res
. 2021 Aug;
10(7):3030-3042.
PMID: 34430345
Background: Malignant pleural mesothelioma (MPM) is a rare malignant tumor associated with asbestos exposure, with infaust prognosis and overall survival below 20 months in treated patients. Platinum is still the...
17.
Brcic L, Mathilakathu A, Walter R, Wessolly M, Mairinger E, Beckert H, et al.
Cancers (Basel)
. 2021 Apr;
13(8).
PMID: 33917061
Malignant pleural mesothelioma (MPM) is an aggressive malignancy associated with asbestos exposure. Median survival ranges from 14 to 20 months after initial diagnosis. As of November 2020, the FDA approved...
18.
Borchert S, Suckrau P, Walter R, Wessolly M, Mairinger E, Steinborn J, et al.
Sci Rep
. 2020 Oct;
10(1):18677.
PMID: 33122816
Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal prognosis. Platinum-based chemotherapy is regularly used as part of multimodality therapy. The expression of metallothioneins (MT) has been...
19.
Wessolly M, Stephan-Falkenau S, Streubel A, Werner R, Borchert S, Griff S, et al.
Cancer Manag Res
. 2020 Sep;
12:7881-7890.
PMID: 32922086
Background: Immune checkpoint inhibition, especially the blockade of PD-1 and PD-L1, has become one of the most thriving therapeutic approaches in modern oncology. Immune evasion caused by altered tumor epitope...
20.
Borchert S, Suckrau P, Wessolly M, Mairinger E, Hegedus B, Hager T, et al.
J Oncol
. 2020 Jan;
2019:2902985.
PMID: 31929796
Background: Malignant pleural mesothelioma (MPM) is a rare, predominantly asbestos-related and biologically highly aggressive tumor associated with a dismal prognosis. Multimodal therapy consisting of platinum-based chemotherapy is the treatment of...